Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 283

1.

The endothelial lectin clearance receptor CLEC4M binds and internalizes Factor VIII in a VWF-dependent and -independent manner.

Swystun LL, Notley C, Georgescu I, Lai JD, Nesbitt K, James PD, Lillicrap D.

J Thromb Haemost. 2019 Feb 11. doi: 10.1111/jth.14404. [Epub ahead of print]

PMID:
30740857
2.

Challenges in diagnosis of von Willebrand disease in the presence of combined mutations of different genes.

Nava T, Dubé E, Gauthier J, Vézina C, Bonnefoy A, Lillicrap D, Rivard GE.

Haemophilia. 2019 Jan 28. doi: 10.1111/hae.13686. [Epub ahead of print] No abstract available.

PMID:
30690834
3.

Abstract thoughts of hemostasis.

Lillicrap D, Morrisey J.

J Thromb Haemost. 2019 Feb;17(2):245. doi: 10.1111/jth.14375. Epub 2019 Jan 15. No abstract available.

PMID:
30644633
4.

Fifty years new.

Lillicrap D, Morrissey JH.

J Thromb Haemost. 2019 Jan;17(1):1. doi: 10.1111/jth.14351. Epub 2018 Dec 16. No abstract available.

PMID:
30556323
5.

Genetic regulation of plasma von Willebrand factor levels in health and disease.

Swystun LL, Lillicrap D.

J Thromb Haemost. 2018 Dec;16(12):2375-2390. doi: 10.1111/jth.14304. Epub 2018 Oct 30. Review.

PMID:
30246494
6.

The endothelial cell receptor stabilin-2 regulates VWF-FVIII complex half-life and immunogenicity.

Swystun LL, Lai JD, Notley C, Georgescu I, Paine AS, Mewburn J, Nesbitt K, Schledzewski K, Géraud C, Kzhyshkowska J, Goerdt S, Hopman W, Montgomery RR, James PD, Lillicrap D.

J Clin Invest. 2018 Aug 31;128(9):4057-4073. doi: 10.1172/JCI96400. Epub 2018 Aug 20.

7.

Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations.

Iorio A, Edginton AN, Blanchette V, Blatny J, Boban A, Cnossen M, Collins P, Croteau SE, Fischer K, Hart DP, Ito S, Korth-Bradley J, Lethagen S, Lillicrap D, Makris M, Mathôt R, Morfini M, Neufeld EJ, Spears J.

Res Pract Thromb Haemost. 2018 May 20;2(3):535-548. doi: 10.1002/rth2.12106. eCollection 2018 Jul. Review.

8.

Advances in Clinical and Basic Science of Coagulation: Illustrated abstracts of the 9th Chapel Hill Symposium on Hemostasis.

Bergmeier W, Antoniak S, Conway EM, Denis CV, George LA, Isermann B, Key NS, Krishnaswamy S, Lam WA, Lillicrap D, Liu J, Looney MR, López JA, Maas C, Peyvandi F, Ruf W, Sood AK, Versteeg HH, Wolberg AS, Wong PC, Wood JP, Weiler H.

Res Pract Thromb Haemost. 2018 Apr 12;2(3):407-428. doi: 10.1002/rth2.12095. eCollection 2018 Jul. Review.

9.

N-linked glycosylation modulates the immunogenicity of recombinant human factor VIII in hemophilia A mice.

Lai JD, Swystun LL, Cartier D, Nesbitt K, Zhang C, Hough C, Dennis JW, Lillicrap D.

Haematologica. 2018 Nov;103(11):1925-1936. doi: 10.3324/haematol.2018.188219. Epub 2018 Jul 12.

10.

The common VWF single nucleotide variants c.2365A>G and c.2385T>C modify VWF biosynthesis and clearance.

Mufti AH, Ogiwara K, Swystun LL, Eikenboom JCJ, Budde U, Hopman WM, Halldén C, Goudemand J, Peake IR, Goodeve AC, Lillicrap D, Hampshire DJ; European Group on von Willebrand disease (EU-VWD) and Zimmerman Program for the Molecular and Clinical Biology of von Willebrand disease (ZPMCB-VWD) Study Groups.

Blood Adv. 2018 Jul 10;2(13):1585-1594. doi: 10.1182/bloodadvances.2017011643.

11.

The Jamaican Haemophilia Registry: Describing the burden of disease.

Wharfe G, Buchner-Daley L, Gibson T, Hilliard P, Usuba K, Abad A, Boma-Fischer L, Bouskill V, Floros G, Lillicrap D, Lowe Y, Lowe D, Palmer-Mitchell N, Rand ML, Teitel J, Tuttle A, Watson A, White R, Young NL, Blanchette VS.

Haemophilia. 2018 Jul;24(4):e179-e186. doi: 10.1111/hae.13517. Epub 2018 May 31.

PMID:
29855125
12.

Dexamethasone promotes durable factor VIII-specific tolerance in hemophilia A mice via thymic mechanisms.

Georgescu MT, Moorehead PC, van Velzen AS, Nesbitt K, Reipert BM, Steinitz KN, Schuster M, Hough C, Lillicrap D.

Haematologica. 2018 Aug;103(8):1403-1413. doi: 10.3324/haematol.2018.189852. Epub 2018 Apr 19.

13.

Tolerogenic properties of the Fc portion of IgG and its relevance to the treatment and management of hemophilia

Blumberg RS, Lillicrap D; IgG Fc Immune Tolerance Group.

Blood. 2018 May 17;131(20):2205-2214. doi: 10.1182/blood-2017-12-822908. Epub 2018 Mar 27. Review.

PMID:
29588277
14.

World bleeding disorders registry: The pilot study.

Coffin D, Herr C, O'Hara J, Diop S, Hollingsworth R, Srivastava A, Lillicrap D, van den Berg HM, Iorio A, Pierce GF.

Haemophilia. 2018 May;24(3):e113-e116. doi: 10.1111/hae.13431. Epub 2018 Feb 1. No abstract available.

PMID:
29388721
15.

Early cellular interactions and immune transcriptome profiles in human factor VIII-exposed hemophilia A mice.

Lai JD, Cartier D, Hartholt RB, Swystun LL, van Velzen AS, den Haan JMM, Hough C, Voorberg J, Lillicrap D.

J Thromb Haemost. 2018 Mar;16(3):533-545. doi: 10.1111/jth.13936. Epub 2018 Feb 2.

PMID:
29285874
16.

FIX It in One Go: Enhanced Factor IX Gene Therapy for Hemophilia B.

Lillicrap D.

Cell. 2017 Dec 14;171(7):1478-1480. doi: 10.1016/j.cell.2017.11.049.

17.

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation.

Michels A, Swystun LL, Mewburn J, Albánez S, Lillicrap D.

J Vis Exp. 2017 Aug 14;(126). doi: 10.3791/55917.

PMID:
28829426
18.

Thrombolytic Potential of N-Acetylcysteine: Evidence for Significant Benefit in Mitigating Arterial Thrombosis.

Lillicrap D.

Circulation. 2017 Aug 15;136(7):661-663. doi: 10.1161/CIRCULATIONAHA.117.029313. No abstract available.

PMID:
28808146
19.

Minimal dataset for post-registration surveillance of new drugs in hemophilia: communication from the SSC of the ISTH.

Peyvandi F, Makris M, Collins P, Lillicrap D, Pipe SW, Iorio A, Rosendaal FR; Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders.

J Thromb Haemost. 2017 Sep;15(9):1878-1881. doi: 10.1111/jth.13762. Epub 2017 Aug 2. No abstract available.

PMID:
28767195
20.

Bispecific Antibody Therapy in Hemophilia.

Lillicrap D.

N Engl J Med. 2017 Aug 31;377(9):884-885. doi: 10.1056/NEJMe1707802. Epub 2017 Jul 10. No abstract available.

PMID:
28691560
21.

Abnormal von Willebrand factor secretion, factor VIII stabilization and thrombus dynamics in type 2N von Willebrand disease mice.

Swystun LL, Georgescu I, Mewburn J, Deforest M, Nesbitt K, Hebert K, Dwyer C, Brown C, Notley C, Lillicrap D.

J Thromb Haemost. 2017 Aug;15(8):1607-1619. doi: 10.1111/jth.13749. Epub 2017 Jul 17.

PMID:
28581694
22.

Discrepant platelet and plasma von Willebrand factor in von Willebrand disease patients with p.Pro2808Leufs*24.

Bowman ML, Pluthero FG, Tuttle A, Casey L, Li L, Christensen H, Robinson KS, Lillicrap D, Kahr WHA, James P.

J Thromb Haemost. 2017 Jul;15(7):1403-1411. doi: 10.1111/jth.13722. Epub 2017 Jun 6.

23.

Factor VIII inhibitors: Advances in basic and translational science.

Lai JD, Lillicrap D.

Int J Lab Hematol. 2017 May;39 Suppl 1:6-13. doi: 10.1111/ijlh.12659. Review.

PMID:
28447409
24.

Biological considerations of plasma-derived and recombinant factor VIII immunogenicity.

Lai J, Hough C, Tarrant J, Lillicrap D.

Blood. 2017 Jun 15;129(24):3147-3154. doi: 10.1182/blood-2016-11-750885. Epub 2017 Apr 21. Review.

25.

Utility of factor VIII and factor VIII to von Willebrand factor ratio in identifying 277 unselected carriers of hemophilia A.

Labarque V, Perinparajah V, Bouskill V, Stain AM, Wakefield C, Manuel C, Blanchette VS, James PD, Lillicrap D, Carcao MD.

Am J Hematol. 2017 Jun;92(6):E94-E96. doi: 10.1002/ajh.24709. Epub 2017 Apr 6. No abstract available.

26.

Summary report of the First International Conference on inhibitors in haemophilia A.

Lacroix-Desmazes S, Scott DW, Goudemand J, Van Den Berg M, Makris M, Van Velzen AS, Santagostino E, Lillicrap D, Rosendaal FR, Hilger A, Sauna ZE, Oldenburg J, Mantovani L, Mancuso ME, Kessler C, Hay CRM, Knoebl P, Di Minno G, Hoots K, Bok A, Brooker M, Buoso E, Mannucci PM, Peyvandi F.

Blood Transfus. 2017 Oct;15(6):568-576. doi: 10.2450/2016.0252-16. Epub 2016 Nov 25. No abstract available.

27.

Histones link inflammation and thrombosis through the induction of Weibel-Palade body exocytosis.

Michels A, Albánez S, Mewburn J, Nesbitt K, Gould TJ, Liaw PC, James PD, Swystun LL, Lillicrap D.

J Thromb Haemost. 2016 Nov;14(11):2274-2286. doi: 10.1111/jth.13493.

28.

Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.

Pipe SW, Montgomery RR, Pratt KP, Lenting PJ, Lillicrap D.

Blood. 2016 Oct 20;128(16):2007-2016. doi: 10.1182/blood-2016-04-713289. Epub 2016 Sep 1. Review.

29.

Recommendations for authors of manuscripts reporting inhibitor cases developed in previously treated patients with hemophilia: communication from the SSC of the ISTH.

Iorio A, Barbara AM, Bernardi F, Lillicrap D, Makris M, Peyvandi F, Rosendaal F; Subcommittee on Factor VIII, Factor IX & Rare Coagulation Disorder.

J Thromb Haemost. 2016 Aug;14(8):1668-72. doi: 10.1111/jth.13382. Epub 2016 Aug 6.

30.

Functional characterisation of the type 1 von Willebrand disease candidate VWF gene variants: p.M771I, p.L881R and p.P1413L.

Berber E, Ozbil M, Brown C, Baslar Z, Caglayan SH, Lillicrap D.

Blood Transfus. 2017 Oct;15(6):548-556. doi: 10.2450/2016.0034-16. Epub 2016 Jul 25.

31.

How much do we really know about von Willebrand disease?

Swystun LL, Lillicrap D.

Curr Opin Hematol. 2016 Sep;23(5):471-8. doi: 10.1097/MOH.0000000000000272. Review.

PMID:
27428891
32.

Alternative therapies for the management of inhibitors.

Shima M, Lillicrap D, Kruse-Jarres R.

Haemophilia. 2016 Jul;22 Suppl 5:36-41. doi: 10.1111/hae.13005.

PMID:
27405674
33.

Gene Therapy for Coagulation Disorders.

Swystun LL, Lillicrap D.

Circ Res. 2016 Apr 29;118(9):1443-52. doi: 10.1161/CIRCRESAHA.115.307015. Review.

PMID:
27126652
34.

Concurrent influenza vaccination reduces anti-FVIII antibody responses in murine hemophilia A.

Lai JD, Moorehead PC, Sponagle K, Steinitz KN, Reipert BM, Hough C, Lillicrap D.

Blood. 2016 Jun 30;127(26):3439-49. doi: 10.1182/blood-2015-11-679282. Epub 2016 Mar 31.

35.

Canine models of inherited bleeding disorders in the development of coagulation assays, novel protein replacement and gene therapies.

Nichols TC, Hough C, Agersø H, Ezban M, Lillicrap D.

J Thromb Haemost. 2016 May;14(5):894-905. doi: 10.1111/jth.13301. Epub 2016 Apr 5. Review.

36.

Platelet type von Willebrand disease and registry report: communication from the SSC of the ISTH.

Othman M, Kaur H, Favaloro EJ, Lillicrap D, Di Paola J, Harrison P, Gresele P; Subcommittees on von Willebrand Disease and Platelet Physiology.

J Thromb Haemost. 2016 Feb;14(2):411-4. doi: 10.1111/jth.13204. Epub 2016 Jan 20. No abstract available.

37.

Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms.

Albánez S, Ogiwara K, Michels A, Hopman W, Grabell J, James P, Lillicrap D.

J Thromb Haemost. 2016 May;14(5):953-63. doi: 10.1111/jth.13294. Epub 2016 Apr 27.

38.

Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States.

Flood VH, Christopherson PA, Gill JC, Friedman KD, Haberichter SL, Bellissimo DB, Udani RA, Dasgupta M, Hoffmann RG, Ragni MV, Shapiro AD, Lusher JM, Lentz SR, Abshire TC, Leissinger C, Hoots WK, Manco-Johnson MJ, Gruppo RA, Boggio LN, Montgomery KT, Goodeve AC, James PD, Lillicrap D, Peake IR, Montgomery RR.

Blood. 2016 May 19;127(20):2481-8. doi: 10.1182/blood-2015-10-673681. Epub 2016 Feb 9.

39.

Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice.

Krishnamoorthy S, Liu T, Drager D, Patarroyo-White S, Chhabra ES, Peters R, Josephson N, Lillicrap D, Blumberg RS, Pierce GF, Jiang H.

Cell Immunol. 2016 Mar;301:30-9. doi: 10.1016/j.cellimm.2015.12.008. Epub 2015 Dec 29.

40.

Foreword.

Lillicrap D.

Eur J Haematol. 2015 Dec;95 Suppl 81:1. doi: 10.1111/ejh.12579. No abstract available.

PMID:
26679391
41.

War and peace: Factor VIII and the adaptive immune response.

Georgescu MT, Lai JD, Hough C, Lillicrap D.

Cell Immunol. 2016 Mar;301:2-7. doi: 10.1016/j.cellimm.2015.11.008. Epub 2015 Nov 28. Review.

PMID:
26676073
42.

Transgene-host cell interactions mediate significant influences on the production, stability, and function of recombinant canine FVIII.

Crawford B, Ozelo MC, Ogiwara K, Ahlin J, Albanez S, Hegadorn C, Harpell L, Hough C, Lillicrap D.

Mol Ther Methods Clin Dev. 2015 Nov 18;2:15033. doi: 10.1038/mtm.2015.33. eCollection 2015.

43.

To clear or to fear: An innate perspective on factor VIII immunity.

Lai JD, Georgescu MT, Hough C, Lillicrap D.

Cell Immunol. 2016 Mar;301:82-9. doi: 10.1016/j.cellimm.2015.10.011. Epub 2015 Oct 28. Review.

PMID:
26547364
44.

Porcine recombinant factor VIII (Obizur; OBI-1; BAX801): product characteristics and preclinical profile.

Lillicrap D, Schiviz A, Apostol C, Wojciechowski P, Horling F, Lai CK, Piskernik C, Hoellriegl W, Lollar P.

Haemophilia. 2016 Mar;22(2):308-317. doi: 10.1111/hae.12784. Epub 2015 Aug 17.

PMID:
26278557
45.

Journal of Thrombosis and Haemostasis. Special Issue: State of the Art 2015. Preface.

Lillicrap D, Douketis J.

J Thromb Haemost. 2015 Jun;13 Suppl 1:S1. doi: 10.1111/jth.12979. No abstract available.

46.

Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease.

Rydz N, Grabell J, Lillicrap D, James PD.

Haemophilia. 2015 Sep;21(5):636-41. doi: 10.1111/hae.12664. Epub 2015 Mar 10.

47.

Introduction to a series of reviews on inherited bleeding disorders.

Lillicrap D.

Blood. 2015 Mar 26;125(13):2011. doi: 10.1182/blood-2015-01-613588. Epub 2015 Feb 23. No abstract available.

48.

Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity.

Oldenburg J, Lacroix-Desmazes S, Lillicrap D.

Haematologica. 2015 Feb;100(2):149-56. doi: 10.3324/haematol.2014.112821. Review.

49.

Rapid acquisition of immunologic tolerance to factor VIII and disappearance of anti-factor VIII IgG4 after prophylactic therapy in a hemophilia A patient with high-titer factor VIII inhibitor.

Moorehead PC, Thibeault L, Tuttle A, Grabell J, Dwyre L, Silva M, James P, Lillicrap D.

J Pediatr Hematol Oncol. 2015 May;37(4):e220-2. doi: 10.1097/MPH.0000000000000287.

PMID:
25411864
50.

Syntaxin-binding protein 5 exocytosis regulation: differential role in endothelial cells and platelets.

Lillicrap D.

J Clin Invest. 2014 Oct;124(10):4231-3. doi: 10.1172/JCI77511. Epub 2014 Sep 17.

Supplemental Content

Loading ...
Support Center